Category: car-t

In the realm of chimeric antigen receptor (CAR) T-cell therapy, particularly in patients grappling with relapsed/refractory large B-cell lymphoma (LBCL), the landscape is rife with manufacturing hurdles. A recent study sourced from 9 UK centers delved into the administration of out-of-specification (OOS) autologous CAR T-cell therapy, shedding light on a path to navigate manufacturing failures […]

Amidst the realm of cell therapies and immunotherapy, a groundbreaking avenue emerges with the advent of BCMA-directed RNA chimeric antigen receptor T-cell therapy (CAR T) for refractory generalized myasthenia gravis. Delving into a realm of innovative treatment strategies, the long-term follow-up data sheds light on patient outcomes at multiple time points, unveiling a tapestry of […]

Multiple myeloma (MM), a challenging blood cancer with a pattern of remissions and relapses, has seen a surge in highly effective treatments in recent years, including T-cell redirecting therapies (TRTs) like CAR-T cells and bispecific antibodies. These innovative therapies have shown remarkable clinical responses, necessitating sophisticated response monitoring tools to guide patient care effectively. Measurable […]

In the ongoing battle against cancer, researchers have uncovered a groundbreaking discovery that could potentially revolutionize cancer immunotherapy. Telomere damage has been identified as a key driver of T cell exhaustion, a phenomenon where these vital immune cells lose their cancer-fighting strength. The hostile tumor environment, characterized by limited oxygen and elevated acidity, places immense […]

In the realm of autoimmune diseases, where the immune system turns against the body’s own tissues, a revolution is underway. The intricate interplay of genetic predispositions, environmental factors, and hormonal fluctuations leads to a myriad of conditions impacting various organ systems, from rheumatoid arthritis to lupus and multiple sclerosis. Despite strides in therapeutic interventions, a […]

Multiple myeloma, a hematologic malignancy characterized by the clonal proliferation of plasma cells in the bone marrow, poses a significant health and economic burden globally. As treatment options for multiple myeloma evolve, understanding the economic implications of these therapies becomes crucial for healthcare providers, policymakers, and researchers. This article delves into the cost-effectiveness of Chimeric […]

Are you ready to delve into the exciting world of cutting-edge cancer immunotherapy? Today, we’re exploring the groundbreaking potential of CAR exosomes derived from effector CAR-T cells. These tiny powerhouses pack a punch with potent antitumour effects while keeping toxicity levels low. Let’s dive in and uncover the innovative science behind this revolutionary approach! Revolutionizing […]

CAR-T cell therapy, a groundbreaking treatment for cancer, is transforming lives. One such success story is Diane Banck, who battled multiple myeloma and triumphantly declared herself cancer-free after undergoing CAR-T therapy at Avera Cancer Institute. Utilizing Chimeric Antigen Receptor technology, CAR-T therapy harnesses a patient’s own T cells to target and destroy cancer cells, offering […]

Integra Therapeutics, a prominent player in the field of gene therapy tools aimed at enhancing the precision, efficacy, and safety of advanced treatments, recently closed a pre-Series A investment round totaling €10.7 million. This funding injection includes contributions from new investors such as the EIC Fund, the venture capital arm of the European Innovation Council […]

The landscape of cancer treatment is undergoing a transformative shift, with CAR-T cell therapy emerging as a promising avenue in the fight against hematologic malignancies. According to Credence Research, the CAR-T Cell Therapy Market is poised for remarkable growth, projected to soar from USD 4,405 million in 2024 to a staggering USD 11,142.53 million by […]

AbbVie recently finalized its acquisition of Capstan Therapeutics, marking a significant milestone in the company’s quest to enhance patient care. The integration of Capstan into AbbVie brings forth promising possibilities, particularly with Capstan’s lead asset CPTX2309, currently undergoing Phase 1 trials for B cell-mediated autoimmune diseases. This asset, a tLNP that fosters the development of […]

AdventHealth Cancer Institute in Orlando is at the forefront of providing a revolutionary treatment called CAR-T cell therapy for cancer patients, particularly those with multiple myeloma. This innovative therapy involves modifying a patient’s immune cells to effectively combat cancer cells, offering a new ray of hope for individuals battling this challenging disease. Dr. Rushang Patel, […]

In the recent second replicate study (Study 1) of the pivotal Phase 3 UP-AA clinical program, AbbVie’s upadacitinib (RINVOQ®) has successfully met its primary endpoint, showcasing significant efficacy with 45.2% and 55.0% of patients achieving positive outcomes. This marks a substantial milestone in advancing treatment options for patients in need. The promising results from this […]

Organoid models have revolutionized drug screening, disease research, and precision medicine with their ability to mimic in vivo organs in a biomimetic microenvironment. Combining organoids with microfluidics in organoid-on-a-chip systems offers precise control over biochemical factors and fluid conditions, enhancing their relevance to clinical applications. While traditional 2D cell cultures and animal models have limitations […]

CAR-T cell therapy has emerged as a groundbreaking approach in treating cancer, offering new hope for patients with unmet medical needs. To further advance this field, it is crucial to establish robust frameworks for analytical development and quality control. The development of rapid, scalable, and reliable analytical tools is essential to ensure the safety, efficacy, […]